Recent successes of cancer immunotherapy: A new dimension in personalized medicine?

Targeted Oncology

Volumn 7, Issue 1, 2012, Pages 1-2

  Caux, Christophe ^a,b,c   Zitvogel, Laurence ^d,e  

^a UNIVERSITÉ LYON 1   (France)

^b CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^c CENTRE LÉON BÉRARD   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 7; IPILIMUMAB; SIPULEUCEL T; TOLL LIKE RECEPTOR AGONIST;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CASTRATION RESISTANT PROSTATE CANCER; CD4+ CD25+ T LYMPHOCYTE; EDITORIAL; HUMAN; IMMUNE EVASION; LYMPHOMA; METASTATIC MELANOMA; NEUROBLASTOMA; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SYNOVIAL SARCOMA; T CELL DEPLETION; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; NEOPLASMS;

EID: 84856793884     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-012-0211-3     Document Type: Editorial

References (16)

1. Rosenberg SA (2011) Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol 8:577-585
2. Jotereau F, Gervois N, Labarrière N Adoptive transfer with high affinity TCR to treat human solid tumours: how to improve the feasibility? Targeted Oncol, this issue doi:10.1007/s11523-012- 0207-z
3. Sharma P,Wagner K, Wolchok JD, Allison JP (2011) Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11:805-812
4. Lesterhuis WJ, Haanen JB, Punt CJ (2011) Cancer immunotherapy- revisited. Nat Rev Drug Discov 10:591-600
5. Melief CJ, van der Burg SH (2008) Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 8:351-360 (Pubitemid 351589701)
6. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175-208
7. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR (2010) Overall survival analysis of a phase II randomized controlled trial of a poxviralbased PSA-targeted immunotherapy in metastatic castrationresistant prostate cancer. J Clin Oncol 28:1099-1105
8. Goutagny N, Estornes Y, Hasan U, Lebecque S, Caux C Targeting pattern recognition receptors in cancer immunotherapy. Targeted Oncol, this issue doi:10.1007/s11523-012-0209-x
9. Morre M, Beq S Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. Targeted Oncol, this issue doi:10.1007/s11523-012-0210-4
10. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263-274 (Pubitemid 40488632)
11. Sakaguchi S (2004) Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531-562 (Pubitemid 38680433)
12. Colombo MP, Piconese S (2007) Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 7:880-887 (Pubitemid 350006256)
13. Ménétrier-Caux C, Curiel T, Faget F, Manuel M, Caux C and Zou W Targeting regulatory T cells. Targeted Oncol, this issue doi:10.1007/s11523-012-0208-y
14. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59-73
15. Zitvogel L, Kepp O, Kroemer G (2011) Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 8:151-160
16. Ogino S, Galon J, Fuchs CS, Dranoff G (2011) Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 8:711-719